Analysts on Wall Street project that Advanced Drainage Systems (WMS) will announce quarterly earnings of $1.11 per share in its forthcoming report, representing an increase of 1.8% year over year. Revenues are projected to reach $686.55 million, declining 0.6% from the same quarter last year.The current level reflects an upward revision of 0.7% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initia ...

Wall Street analysts forecast that Boston Scientific (BSX) will report quarterly earnings of $0.78 per share in its upcoming release, pointing to a year-over-year increase of 11.4%. It is anticipated that revenues will amount to $5.27 billion, exhibiting an increase of 15.4% compared to the year-ago quarter.Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the cours ...

Core Viewpoint - Analysts expect SEI Investments (SEIC) to report quarterly earnings of $1.34 per share, reflecting a year-over-year increase of 12.6%, with revenues projected at $595.79 million, up 6.9% from the previous year [1]. Earnings Estimates - The consensus EPS estimate has been revised 0.9% higher over the last 30 days, indicating a collective reevaluation by analysts [1][2]. Revenue Projections - Revenue from Asset management, administration, and distribution fees is expected to be $472.28 million, a 7.5% increase year-over-year [4]. - Revenue from Information processing and software servicing fees is projected at $123.71 million, reflecting a 5.1% increase from the prior year [4]. - Revenue from Private Banks is anticipated to be $147.29 million, also a 5.1% increase from the previous year [5]. - Revenue from Investments in New Business is expected to decline to $9.59 million, a significant decrease of 38.9% year-over-year [5]. Assets Under Management - Assets under management for Investments in New Business are estimated at $3.16 billion, up from $3.04 billion year-over-year [5]. - Assets under management for Investment Advisors are projected to reach $97.05 billion, compared to $79.39 billion last year [6]. - Assets under management for Private Banks are expected to be $31.45 billion, an increase from $28.22 billion year-over-year [6]. - Institutional Investors' assets under management are forecasted to be $85.14 billion, up from $76.99 billion in the same quarter last year [7]. - Assets under management for LSV - Equity and Fixed Income programs are estimated at $82.09 billion, down from $86.50 billion year-over-year [7]. - Total assets under management for Investment Managers are projected to reach $240.47 billion, up from $202.57 billion last year [8]. Client Assets Under Administration - Client assets under administration for Investment Managers are expected to reach 1,223,549, compared to 1,032,812 in the previous year [8]. - Client assets under administration for Private Banks are projected to be 8,713, an increase from 8,340 year-over-year [9]. Stock Performance - Over the past month, SEI shares have returned +1.5%, outperforming the Zacks S&P 500 composite's +0.4% change, indicating a positive outlook for the stock [10].

Wall Street analysts forecast that Visa (V) will report quarterly earnings of $3.14 per share in its upcoming release, pointing to a year-over-year increase of 14.2%. It is anticipated that revenues will amount to $10.69 billion, exhibiting an increase of 12.4% compared to the year-ago quarter.Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Ahead of a com ...

Core Insights - Analysts project Corning (GLW) will report quarterly earnings of $0.70 per share, reflecting a 22.8% year-over-year increase, with revenues expected to reach $4.32 billion, an 11.6% increase from the same quarter last year [1] Earnings Estimates - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analysts' assessments [1][2] - Changes in earnings estimates are crucial for predicting investor reactions, as empirical research shows a strong correlation between earnings estimate revisions and short-term stock performance [2] Key Metrics Forecast - Analysts estimate 'Net Sales- Display Technologies' at $880.85 million, a decrease of 9.3% year over year [4] - 'Net Sales- Hemlock and Emerging Growth Businesses' is projected at $464.86 million, an increase of 24.6% year over year [4] - 'Net Sales- Specialty Materials' is expected to reach $587.56 million, indicating a 14.1% increase from the prior-year quarter [4] Segment Sales and Income - The consensus for 'Net Sales- Life Sciences' is $249.13 million, showing a slight decline of 0.4% year over year [5] - 'Net Sales- Optical Communications' is forecasted at $1.71 billion, reflecting a 24.8% increase from the year-ago quarter [5] - 'Segment Net Income- Display Technologies' is expected to be $216.95 million, down from $262.00 million in the same quarter last year [5][6] - 'Segment Net Income- Life Sciences' is projected at $17.35 million, compared to $18.00 million a year ago [6] - 'Segment Net Income- Optical Communications' is anticipated to reach $261.29 million, up from $194.00 million last year [6] - 'Segment Net Income- Specialty Materials' is estimated at $98.80 million, compared to $81.00 million in the previous year [7] Stock Performance - Over the past month, Corning's shares have returned +5.2%, outperforming the Zacks S&P 500 composite's +0.6% change [7] - Corning currently holds a Zacks Rank 2 (Buy), suggesting potential outperformance in the near future [7]

Core Insights - Analysts project that Bally's (BALY) will report a quarterly loss of -$0.71 per share, reflecting a year-over-year increase of 64.3% [1] - Revenue is expected to reach $659.65 million, marking a 4.7% increase from the same quarter last year [1] - The consensus EPS estimate has remained unchanged over the past 30 days, indicating a reassessment by covering analysts [1] Revenue Estimates - Analysts estimate 'Revenue- Casinos & Resorts' at $392.60 million, representing an 11.1% increase from the prior-year quarter [4] - 'Revenue- International Interactive' is projected to be $211.30 million, indicating a decline of 8.5% from the year-ago quarter [4] - 'Revenue- North America Interactive' is expected to reach $54.80 million, reflecting a 20% increase from the prior-year quarter [4] EBITDAR Estimates - 'Adjusted EBITDAR- International Interactive' is expected to be $82.90 million, down from $90.03 million reported in the same quarter last year [5] - Analysts project 'Adjusted EBITDAR- Casinos & Resorts' at $109.15 million, compared to $100.44 million from the previous year [5] Stock Performance - Over the past month, shares of Bally's have increased by 28%, while the Zacks S&P 500 composite has only risen by 1.3% [5] - Currently, Bally's holds a Zacks Rank 3 (Hold), suggesting its performance may align with the overall market in the near future [5]

Core Insights - American Healthcare REIT (AHR) is expected to report quarterly earnings of $0.42 per share, reflecting a year-over-year increase of 16.7% [1] - Projected revenues for AHR are anticipated to be $565.26 million, which represents a 7.9% increase from the same quarter last year [1] - The consensus EPS estimate has remained stable over the last 30 days, indicating a collective reevaluation by analysts [1] Revenue Estimates - Analysts predict 'Revenues- Resident fees and services' to be $535.68 million, showing a year-over-year increase of 12.3% [4] - The consensus estimate for 'Revenues- Real estate revenue' is $39.47 million, indicating a decline of 16% from the prior-year quarter [4] Other Financial Metrics - 'Depreciation and amortization' is forecasted to reach $42.39 million [5] - AHR shares have increased by 12% over the past month, outperforming the Zacks S&P 500 composite, which saw a 1% increase [5] - AHR holds a Zacks Rank 2 (Buy), suggesting it is expected to outperform the overall market in the near future [5]

Core Insights - Analysts project that Enterprise Products Partners (EPD) will report quarterly earnings of $0.67 per share, reflecting a year-over-year increase of 3.1% [1] - Revenue is expected to reach $12.59 billion, which represents an 8.6% decline from the same quarter last year [1] - The consensus EPS estimate has been revised downward by 1.7% in the past 30 days, indicating a reassessment by covering analysts [2] Financial Metrics - Analysts estimate 'NGL Pipelines & Services net - NGL fractionation volumes per day' at 1,719.13 thousand barrels, up from 1,611.00 thousand barrels a year ago [5] - The forecast for 'NGL Pipelines & Services net - Fee-based natural gas processing per day' is 7,711.24 thousand barrels, compared to 6,804.00 thousand barrels last year [5] - The consensus for 'NGL Pipelines & Services net - NGL pipeline transportation volumes per day' is 4,562.86 thousand barrels, an increase from 4,223.00 thousand barrels in the same quarter last year [6] - 'Natural Gas Pipelines & Services net - Natural gas transportation volumes per day' are estimated at 20,723 billion British thermal units, up from 19,090 billion British thermal units a year ago [7] - 'Petrochemical Services net - Butane isomerization volumes per day' are expected to be 120.61 thousand barrels, compared to 116.00 thousand barrels last year [7] - 'Petrochemical Services net - Propylene fractionation volumes per day' is projected at 113.58 thousand barrels, slightly up from 113.00 thousand barrels a year ago [8] - 'Petrochemical Services net - Octane enhancement and related plant sales volumes per day' is expected to reach 38.03 thousand barrels, compared to 37.00 thousand barrels last year [9] Operating Margins - 'NGL Pipelines & Services' gross operating margin is forecasted to be $1.37 billion, compared to $1.34 billion last year [10] - 'Crude Oil Pipelines & Services' gross operating margin is projected at $377.00 million, down from $401.00 million in the same quarter last year [11] - 'Natural Gas Pipelines & Services' gross operating margin is expected to reach $402.33 million, up from $349.00 million a year ago [11] - 'Petrochemical & Refined Products Services' gross operating margin is estimated at $343.04 million, compared to $363.00 million last year [12] Stock Performance - Over the past month, shares of Enterprise Products have returned -0.3%, while the Zacks S&P 500 composite has changed by +3.6% [12] - Currently, EPD holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the overall market in the near future [12]

Core Viewpoint - Analysts project Novartis (NVS) will report quarterly earnings of $2.26 per share, reflecting a 9.7% year-over-year increase, with revenues expected to reach $13.9 billion, an 8.4% increase from the same quarter last year [1]. Earnings Estimates - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a collective reevaluation by analysts [1][2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical research shows a strong correlation between earnings estimate revisions and short-term stock performance [2]. Revenue Projections - Analysts expect 'Revenues- Oncology- Tafinlar + Mekinist- Total' to be $555.75 million, a 4.1% increase year-over-year [4]. - 'Revenues- Net sales to third parties' are projected to reach $14.07 billion, indicating a 9.8% year-over-year change [4]. - 'Revenues- Oncology- Kisqali- Total' is estimated at $1.29 billion, reflecting a significant 64.2% year-over-year increase [4]. Specific Revenue Metrics - 'Revenues- Immunology- Cosentyx- Total' is expected to reach $1.72 billion, a 1.9% increase from the prior year [5]. - 'Revenues- Oncology- Tasigna- US' is projected at $119.43 million, showing a decline of 47.2% year-over-year [5]. - 'Revenues- Oncology- Promacta/Revolade- US' is estimated at $180.08 million, indicating a 41.2% decrease from the year-ago quarter [5]. Additional Revenue Insights - 'Revenues- Immunology- Cosentyx- US' is expected to be $990.42 million, a slight decrease of 0.3% year-over-year [6]. - 'Revenues- Cardiovascular- Entresto- US' is projected at $927.94 million, reflecting a 1.8% increase from the previous year [6]. - 'Revenues- Oncology- Tasigna- ROW' is estimated at $149.03 million, indicating a 22.8% decline year-over-year [7]. - 'Revenues- Oncology- Tafinlar + Mekinist- ROW' is expected to reach $320.55 million, a 4.4% increase year-over-year [7]. - 'Revenues- Oncology- Promacta/Revolade- ROW' is projected at $267.72 million, reflecting a 1.8% increase [7]. - 'Revenues- Immunology- Cosentyx- ROW' is expected to be $734.58 million, indicating a 4.9% increase from the prior year [8]. Stock Performance - Novartis shares have increased by 6.9% over the past month, outperforming the Zacks S&P 500 composite, which saw a 0.2% increase [8].

Core Viewpoint - Nutrien (NTR) is expected to report quarterly earnings of $2.40 per share, a 2.6% increase year-over-year, with revenues projected at $10.61 billion, reflecting a 4.5% year-over-year growth [1]. Earnings Estimates - Over the last 30 days, the consensus EPS estimate has been revised upward by 14.2%, indicating analysts' reassessment of their initial forecasts [2]. - Changes in earnings estimates are crucial for predicting investor reactions to the stock, as empirical research shows a strong correlation between earnings estimate revisions and short-term stock price performance [3]. Revenue Projections - Analysts project 'Sales- Retail (Nutrient Ag Solutions)- Total' to reach $8.40 billion, a year-over-year increase of 4.1% [5]. - The consensus estimate for 'Sales- Nitrogen' is $1.25 billion, indicating a 4.9% increase from the previous year [5]. - 'Sales- Potash' is estimated at $892.38 million, reflecting a 6.7% year-over-year change [5]. - 'Sales- Phosphate' is expected to be $436.29 million, showing a decline of 3.3% from the prior year [6]. Sales Volumes - 'Potash - Sales volumes - Total' is projected at 3,613 thousand tons, up from 3,563 thousand tons year-over-year [6]. - 'Nitrogen - Sales volumes - Total' is expected to reach 2,947 thousand tons, compared to 2,818 thousand tons in the same quarter last year [7]. - 'Phosphate - Sales volumes - Total' is forecasted at 575 thousand tons, down from 584 thousand tons year-over-year [8]. - 'Potash - Sales volumes - North America' is estimated at 1,004 thousand tons, compared to 914 thousand tons in the same quarter last year [9]. - 'Nitrogen - Sales volumes - Ammonia' is projected to be 738 thousand tons, up from 698 thousand tons year-over-year [10]. Price Projections - The average selling price per tonne for 'Phosphate - Industrial and feed' is expected to be $755, down from $830 year-over-year [7]. - The average selling price per tonne for 'Phosphate - Total' is projected at $651, compared to $667 in the previous year [8]. Stock Performance - Nutrien shares have decreased by 1.4% over the past month, contrasting with the Zacks S&P 500 composite's increase of 2.3% [11].